Evidence map›Paper›PMID 36787115›Full record

ArticleCancer research2023

Neutrophil Conversion to a Tumor-Killing Phenotype Underpins Effective Microbial Therapy.

Andrew O Yam, Jacqueline Bailey, Francis Lin, Arnolda Jakovija, Scott E Youlten, Claudio Counoupas, Matthias Gunzer, Tobias Bald, Trent M Woodruff, James A Triccas and 4 more

Open access · hybridAbstract read
In one paragraph

Article in Cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Albumin-Bound STING Agonist Reprograms HSPCs to Antitumor Neutrophils Enhancing CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  4. Review
  5. Review
  6. Targeting neutrophils for cancer therapy.Nature reviews. Drug discovery · 2025
    Review
  7. Article
  8. Review
  9. Harnessing myeloid cells in cancer.Molecular cancer · 2025
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 2 countries.

Andrew O YamGarvan Institute of Medical Research, Sydney, New South Wales, Australia.ORCID 0000-0001-8153-7544
Jacqueline BaileyGarvan Institute of Medical Research, Sydney, New South Wales, Australia.ORCID 0000-0001-6256-5582
Francis LinGarvan Institute of Medical Research, Sydney, New South Wales, Australia.ORCID 0000-0001-6913-2245
Arnolda JakovijaGarvan Institute of Medical Research, Sydney, New South Wales, Australia.ORCID 0000-0003-4863-3803
Scott E YoultenKinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.ORCID 0000-0001-9314-2945
Claudio CounoupasDiscipline of Infectious Diseases and Immunology, School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia.ORCID 0000-0002-0283-4004
Matthias GunzerInstitute for Experimental Immunology and Imaging, University Hospital, University Duisburg-Essen, Essen, Germany.ORCID 0000-0002-5534-6055
Tobias BaldInstitute of Experimental Oncology University Hospital Bonn Venusberg-Campus 1, Bonn, Germany.ORCID 0000-0003-0061-235X
Trent M WoodruffSchool of Biomedical Sciences, The University of Queensland, Research Road, St Lucia, Brisbane, Queensland, Australia.ORCID 0000-0003-1382-911X
James A TriccasDiscipline of Infectious Diseases and Immunology, School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia.ORCID 0000-0003-3730-2339
Leonard D GoldsteinKinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.ORCID 0000-0003-4645-553X
David Gallego-OrtegaKinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Sydney, New South Wales, Australia.ORCID 0000-0002-2347-7835
Shane T GreyGarvan Institute of Medical Research, Sydney, New South Wales, Australia.ORCID 0000-0003-2160-1625
Tatyana ChtanovaGarvan Institute of Medical Research, Sydney, New South Wales, Australia.ORCID 0000-0003-3419-4483
Garvan Institute of Medical Research · AUThe University of Sydney · AULeibniz Institute for Analytical Sciences - ISAS · DEThe University of Queensland · AUUniversity Hospital Bonn · DEUniversity of Technology Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The inflammatory microenvironment of solid tumors creates a protumorigenic milieu that resembles chronic inflammation akin to a subverted wound healing response. Here, we investigated the effect of converting the tumor microenvironment from a chronically inflamed state to one of acute microbial inflammation by injecting microbial bioparticles directly into tumors. Intratumoral microbial bioparticle injection led to rapid and dramatic changes in the tumor immune composition, the most striking of which was a substantial increase in the presence of activated neutrophils. In situ photoconversion and intravital microscopy indicated that tumor neutrophils transiently switched from sessile producers of VEGF to highly motile neutrophils that clustered to make neutrophil-rich domains in the tumor. The neutrophil clusters remodeled tumor tissue and repressed tumor growth. Single-cell transcriptional analysis of microbe-stimulated neutrophils showed a profound shift in gene expression towards heightened activation and antimicrobial effector function. Microbe-activated neutrophils also upregulated chemokines known to regulate neutrophil and CD8+ T-cell recruitment. Microbial therapy also boosted CD8+ T-cell function and enhanced the therapeutic benefit of checkpoint inhibitor therapy in tumor-bearing mice and provided protection in a model of tumor recurrence. These data indicate that one of the major effector mechanisms of microbial therapy is the conversion of tumor neutrophils from a wound healing to an acutely activated cytotoxic phenotype, highlighting a rationale for broader deployment of microbial therapy in the treatment of solid cancers. SIGNIFICANCE: Intratumoral injection of microbial bioparticles stimulates neutrophil antitumor functions, suggesting pathways for optimizing efficacy of microbial therapies and paving the way for their broader utilization in the clinic.

Indexed as

NeoplasmsNeutrophilsAnimalsCD8-Positive T-LymphocytesInflammationMiceNeutrophil InfiltrationPhenotypeTumor Microenvironment

Identifiers

PMID36787115
PMCPMC10102850
OpenAlexW4320709972

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.